The Future of Medical Weight Loss in Denver: Foundayo, Oral GLP-1s, and Muscle Protection
The next year of obesity treatment is going to look vastly different than the last — for patients in Denver and everywhere along the Front Range. A new oral GLP-1 launched last month, and shortly before that, a Phase 2 trial showed 30.4% weight loss with a two-drug combination — numbers we’d never seen outside of bariatric surgery. The pattern is clear: better efficacy, fewer barriers, and combinations that protect muscle while burning fat.
The Headline Study: Bimagrumab Plus Semaglutide
A Phase 2 randomized trial published in Nature Medicine paired bimagrumab with semaglutide. Bimagrumab is an injectable that blocks myostatin, helping the body build and protect lean muscle mass. At 26 weeks, the results were striking:
| Treatment Group | Weight Loss at 26 Weeks |
|---|---|
| Semaglutide Alone | 9.5% |
| Bimagrumab Alone | 10.4% |
| Bimagrumab + Semaglutide | 30.4% |
Two mechanisms, working together, achieved roughly three times the weight loss that either medication produced alone. While GLP-1 medications are highly effective for reducing weight, up to 40% of what is lost can be lean muscle. A drug combination that actively protects and builds muscle while you lose body fat is a true medical breakthrough, not just a marketing claim.
Orforglipron Is Now Approved. Call It Foundayo.
Eli Lilly’s orforglipron received FDA approval on April 1, 2026 for chronic weight management. Marketed as Foundayo, it is the first small-molecule oral GLP-1 to come through. Here is what sets it apart:
- No fasting required. Unlike oral peptide options, Foundayo can be taken at any time of day — no empty stomach, no waiting to eat.
- Superior to oral semaglutide. The ACHIEVE-3 trial showed better HbA1c improvements and greater weight loss compared to oral Wegovy.
- Starting at $149/month. Self-pay cost is $149/month for the starting dose, with higher maintenance doses ($299/month for 14.5 mg and 17.2 mg) refilled within a 45-day window.
For Colorado patients who hate needles, or whose insurance covers oral medications but not injectables, Foundayo represents the most practical development in obesity medicine today.
Why Oral Wegovy Has an Adherence Problem
The oral GLP-1 category is filling up fast — and about to get much more competitive. Beyond Foundayo, two drugs are making noise in Phase 2 trials:
- Aleniglipron (Phase 2): about 12% weight loss at 36 weeks, published in Nature Medicine.
- Survodutide (Phase 2b): 11.8% weight loss at 36 weeks, from Boehringer Ingelheim.
Both are meaningful numbers — but they are still oral peptides, which means they come with the same fasting requirement that has made oral Wegovy so hard to stay on. Oral Wegovy must be taken on an empty stomach with a sip of water, followed by a 30-minute wait before eating or drinking. Because of these barriers, the real-world completion rate for oral Wegovy sits at just 16.6%. Sixteen percent. If you have ever wondered why your friend quit their oral GLP-1 after a week, that number explains it.
The Bottom Line for Colorado Patients
If you are already on a GLP-1 and losing weight — stay the course. If you have been waiting for an effective daily pill without fasting rules, Foundayo has arrived. If you are concerned about muscle loss on a GLP-1, ask your doctor about the bimagrumab combination trial and whether you might be a candidate.
These are real tools with real evidence. If you’ve been waiting for the right moment to start — or restart — this is it. If you’re in the Denver area and want a doctor who follows this space closely, give us a call — (303) 750-9454.
Frequently Asked Questions
Is orforglipron (Foundayo) available now, and do I need to fast before taking it?
Yes. Foundayo is FDA-approved for chronic weight management. Unlike oral Wegovy, Foundayo is a non-peptide oral GLP-1 that can be taken at any time of day with no restrictions on food or water intake.
How much does Foundayo cost?
Through manufacturer self-pay programs, the starting dose is $149/month. Higher maintenance doses (14.5 mg and 17.2 mg) cost $299/month when refilled within 45 days.
What is the bimagrumab and semaglutide combination?
A Phase 2 study paired bimagrumab — an injectable that blocks myostatin to protect and build muscle — with semaglutide. Participants lost 30.4% of their body weight at 26 weeks, roughly three times what either drug produced alone.
Will I lose muscle on a GLP-1?
Up to 40% of weight lost on traditional GLP-1s can be lean mass. Bimagrumab specifically addresses this by blocking myostatin to protect and build muscle while you lose fat.
Why do so many people quit oral Wegovy, and what are the alternatives?
Oral Wegovy requires a strict 30-minute empty-stomach fasting period before each dose. Real-world completion rate: 16.6%. Foundayo is now the most practical alternative — no fasting required.
I am already on a GLP-1. Should I switch?
If you are making progress, stay the course. Foundayo is most relevant for people who cannot tolerate injectables, prefer a daily pill, or whose insurance only covers oral medications.
Dr. Ethan Lazarus, MD, is a Diplomate of the American Board of Obesity Medicine and the American Board of Family Medicine. Clinical Nutrition Center is located at 5995 Greenwood Plaza Blvd, Suite 150, Greenwood Village, CO 80111. Call (303) 750-9454 to schedule an appointment.
